Introduction {#s1}
============

Acute Herpetic Neuralgia is characterized by burning, aching, electric shock like pain, or unbearable itching in association with the outbreak of herpes zoster rash.^[@R1]^ The pain is associated with dysesthesias, paresthesias, hyperalgesia, hyperesthesia with allodynia (production of pain by innocuous stimuli) and the severity of zoster increases with age.^[@R2]^ The International Herpes Management Forum (IHMF®) defines "Acute Herpetic Neuralgia" as the pain from onset of prodrome to 30 days; pain between 30 days from prodrome onset to 4 months is "Subacute Herpetic Neuralgia" and pain persisting beyond 4 months from onset of the prodrome of Herpes zoster is "Post Herpetic Neuralgia".^[@R3]^

There are multiple studies on management of PHN but little has been explored on acute Herpetic Neuralgia. Conventionally, the treatments used for pain alleviation in acute Herpetic Neuralgia are NSAIDS, oxycodone and morphine etc. having variable efficacy.^[@R4]^ There are studies with certain other drugs like amitryptyline and nortryptyline, but these drugs, even though being effective, have more disturbing side effects.^[@R5]^

Pregabalin is used for various neuropathic painful conditions.^[@R6],[@R7]^ However, its role in acute pain of zoster has not been explored. This study was done to evaluate the efficacy and safety of Pregabalin in patients with acute Herpetic Neuralgia.

Methods {#s2}
=======

The study was done between May 2009 to April 2011, including patients with acute Herpes zoster presenting within 72 hours of onset, having pain rating 50 or above at baseline on 100mm linear Visual Analogue Scale(VAS). This study was a double blind controlled trial. The subjects were controlled for age and sex. They were assigned into two groups to receive Pregabalin 150mg/day and placebo. At each visit (weeks 0, 1, 2, 3 and 4) subjects were assessed for pain on 100-mm Linear VAS and adverse events were recorded. Eligible subjects who gave informed written consent underwent physical examination. Blood samples were taken for routine hematology and chemistry. Medical histories and demographics were obtained. Oral acyclovir 800mg was given 5 times per day for 7 days to all patients of herpes zoster. The study was approved from the Institutional ethical committee.

Exclusion criteria included the following patients: Acute Herpes zoster presenting after 72 hours of onset; pain of Herpes zoster rating less than 50 at baseline; prior treatment with Pregabalin; history of hypersensitivity to the drug or its ingredients; significant hematological derangements; immuno-compromised state; significant systemic disease or hepatic and renal disease.

Statistical analysis {#s2a}
--------------------

For statistical analysis two-Sample Independent "*t*" test and "Hartley's *f* test" for equality of variance was applied by using Epi Info software for the comparison of the safety and efficacy of Pregabalin with placebo. Probability value of less than 0.05 (p\<0.05) was considered statistically significant.

Results {#s3}
=======

A total of 237 patients visited the Dermatology clinic for Herpes zoster during the study period. Of these, 45 patients were eligible for the study according to inclusion and exclusion criteria. The disease characteristic of the patients showed that the most common area of localization was thoracic followed by lumbar region. The mean time since zoster onset was ranging from 49-51 hours and the mean VAS score was between 81-83 at first visit ([Table 1](#table_1){ref-type="table"}).

Pain assessment in patients by VAS showed continuous decrease VAS in Pregabalin treated group till 4^th^ week ([Table 2](#table_2){ref-type="table"}). Change in VAS was highly significant (p\<0.001) as compared with placebo by using two sample independent "*t*" test and "Hartley's *f* test" for equality of variance ([Table 3](#table_3){ref-type="table"}).

Safety and adverse effects {#s3a}
--------------------------

Most frequently reported adverse effects were somnolence (mean = 26.97%), dizziness (mean = 14.95%) and gastrointestinal (mean = 6.49%) in patients receiving Pregabalin 150 mg/day. The adverse effects were higher in frequency and intensity in first two weeks of therapy and thereafter were reduced in 3^rd^ to 4^th^ week ([Table 4](#table_4){ref-type="table"}).

###### Demographic and disease characteristic of the patients

  -----------------------------------------------------------------------------------------------
  **Characteristics**                 **Oral pregabalin**\   **Placebo**\   **p**\       
                                      **150 mg (n = 23)**    **(n = 22)**   **value**    
  ----------------------------------- ---------------------- -------------- ------------ --------
  Sex                                 Male                   19(82.60%)     17(77.27%)   N.S.\*

  Female                              4(17.39%)              5(22.72%)                   

  Age (in years)                      Mean                   46             47           N.S.

  Range                               31-57                  29-58                       

  Localization                        Trigeminal             2(8.69%)       2(9.09%)     N.S.

  Cervical                            1(4.34%)               1(4.54%)                    

  Thoracic                            16(69.56%)             16(72.72%)                  

  Lumbar                              4(17.39%)              3(13.63%)                   

  Mean time since zoster (in hours)   49                     51             N.S.         

  Mean Base line VAS score (pain)     83                     81             N.S.         
  -----------------------------------------------------------------------------------------------

\* Non Significant

###### Summary of average (mean) pain score on 100 mm linear visual analogue scale

  ------------------------------------------------------------------------------------------
  **Drug dosage**          **Mean VAS score**   **S.D.\* at 4^th^**\                  
                                                **week**                              
  ------------------------ -------------------- ---------------------- ---- ---- ---- ------
  Placebo                  81                   82                     76   74   74   3.03

  Pregabalin (150mg/day)   82                   78                     65   52   53   5.85
  ------------------------------------------------------------------------------------------

\*Standard deviation

###### Results of Two-Sample Independent "*t*" Test between pregabalin treated and placebo groups after 4 weeks

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Result**                             ***t* statistics**   ***df***                       **p-value\***   **Mean Difference**   **Lower Limit**   **Upper Limit**
  -------------------------------------- -------------------- ------------------------------ --------------- --------------------- ----------------- -----------------
  **Equal variance**                     --15.016             43                             \<0.0000001     --21                  --23.82           --18.18

  **Unequal variance**                   --15.214             33                             \<0.0000001     --21                  --23.808          --18.19

                                         ***F***\             ***df(degree of freedom)***\   **p-value\***                                           
                                         **statistics**       **(numerator, denominator)**                                                           

  **Test for equality of variance^†^**   3.72758              22,21                          0.003737                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* p-value (two-tailed),

^†^ Hartley's *f* test for equality of variance

###### Adverse effects in patients administered pregabalin 150 mg/day

  **Adverse effect**   **Week 1**   **Week 2**   **Week 3**   **Week 4**   
  -------------------- ------------ ------------ ------------ ------------ ------
  Somnolence           38.5%        31.4%        21.5%        16.5%        
  Dizziness            19.4%        16.5%        12.4%        11.5%        
  Gastro-intestinal    Dry mouth    14.5%        12.5%        7.5%         4.5%
  Constipation         9.5%         8.7%         5.6%         3.5%         
  Diarrhoea            4.8%         3.2%         2.4%         1.5%         

Discussion {#s4}
==========

Acute herpetic neuralgia is a painful condition which is almost always experienced by patients suffering from herpes zoster and is much more common than post herpetic neuralgia.^[@R2]^ Pregabalin is a calcium channel alpha-2δ ligand with analgesic, anxiolytic, and anticonvulsant properties that acts both centrally and peripherally.^[@R8]^ Pregabalin has been studied for the cases of post herpetic neuralgia and the drug has shown promising results.^[@R6],[@R9],[@R10]^ But the role of Pregabalin has not been studied for sustained relief of pain in acute Herpetic Neuralgia.

In the present study, Pregabalin was administered for 4 weeks, and pain was assessed on VAS and was analyzed every week. Pregabalin showed significantly better response in comparison to placebo (p\<0.0001). The effect was manifested as early as at the end of first week and the optimum response was observed at the end of second week, which continued till the end of therapy.

The only report available for the effective use of Pregabalin in acute Herpetic Neuralgia with single oral dose of 150 mg is by Jensen-dahm *et al*.^[@R11]^ In the above mentioned study which enrolled 8 patients without any controls, the observation period was for 6 hours. In this study reduction of pain was 33% at the end of 6 hours. In the present study which included 23 patients (with 22 controls), the patients were kept under surveillance for a period of 4 weeks. The reduction in pain perception was 55.42% at the end of 4^th^ week of therapy. The results indicate that repeat daily administration of Pregabalin is more effective as compared to single stat dose administration. The reason for better response in our study could be due to sustained level of drug for 4 weeks, leading to steady reduction in pain.

The adverse effects observed include somnolence, dizziness and gastrointestinal disturbance. None of these was severe or serious enough to call for discontinuation of the drug. Patients tolerated the reactions without much discomfort. In studies where Pregabalin was used for post Herpetic Neuralgia in a dose of 600 mg or more, the adverse reactions were higher.^[@R6],[@R9],[@R10]^ These ranged from high percentage of somnolence, dizziness and ataxia as compared to present study. The fewer side effects in the present study could be assigned to smaller amount of drug used i.e. 150 mg per day. This can also be explained by linear gastrointestinal absorption and minimal metabolization of the drug with no known drug-drug interactions and is excreted unchanged from the kidneys.^[@R8]^

The study shows that Pregabalin is efficacious with safe profile in the dose of 150 mg/day in acute Herpetic Neuralgia.
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